1059 results about "Rhamnose" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The application provides a lactobacillus rhamnosus GS044 and a lyophilized powder and a probiotic of the lactobacillus rhamnosus GS044 in application to promoting growth and development and improving immunity, and belongs to the technical field of microorganisms.The application provides a lactobacillus rhamnosus GS044 with a preservation number of CGMCC No.33713.The application further provides a method for preparing gamma-aminobutyric acid by using the lactobacillus rhamnosus GS044, and a lyophilized powder prepared by using the lactobacillus rhamnosus GS044, a probiotic and application of the lyophilized powder and the probiotic.The lyophilized powder and the probiotic prepared by the application can effectively promote growth and development and improve immunity.

The application discloses a kind of traditional Chinese medicine rose flower fermentation method and fermentation composition, it is related to fermentation technical field.The traditional Chinese medicine rose flower fermentation method includes: traditional Chinese medicine rose flower is crushed, mixed with water, and after sterilization, fermentation base material is obtained, yeast peptone solution is added, as blank fermentation pre-liquid;Activated rhamnolipid lactose casein bacillus liquid is inoculated in blank fermentation pre-liquid, and fermentation is carried out.The traditional Chinese medicine rose flower fermentation method provided by the application uses traditional Chinese medicine rose flower as raw material, and utilizes activated rhamnolipid lactose casein bacillus liquid to ferment, without adding exogenous sugar in the fermentation process, but before fermentation, yeast peptone is added first, the addition of yeast peptone can supplement nitrogen source for the fermentation process of subsequent activated rhamnolipid lactose casein bacillus liquid, so that the nutrient content of fermented rose flower is more, and component conversion is more thorough.It is favorable to improve the DPPH free radical scavenging rate, total phenol content and antioxidant property of fermentation composition.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The application provides a Huangdache oligosaccharide with GLP-1 agonist activity and application thereof, and belongs to the technical field of medicines. 3 The oligosaccharide component ELYP-3 has a molecular weight of 3.2*10 3 Da, and the molar ratio of monosaccharides is rhamnose:galacturonic acid:glucose:galactose:arabinose = 1:32.42:45.37:9.11:6.54. The Huangdache oligosaccharide fragment obtained by glycosidase degradation has significant hypoglycemic and weight loss activities, the preparation process is simple, specific and green, and provides scientific basis and theoretical support for the development of natural GLP-1 agonists. Meanwhile, the functional oligosaccharide provides a wide application prospect for the development of medicines with blood glucose regulation.

The invention belongs to the technical field of microorganisms, and discloses lactobacillus rhamnosus capable of relieving toxicity of heavy metal cadmium and application of the lactobacillus rhamnosus. The lactobacillus rhamnosus is preserved in the China Center for Type Microbiological Culture Collection, the preservation address is Wuhan University, Hubei province, and the preservation number is CCTCC No.M20241815. The lactobacillus rhamnosus is named lactobacillus rhamnosus. The lactobacillus rhamnosus provided by the invention is derived from intestinal tracts of healthy stichopus japonicus, has good heavy metal cadmium tolerance and removal capacity, and is expected to be developed and applied to the healthy food industry.

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.

The invention discloses a preparation method of high-stability beta-glucan yoghourt. Mixing the sterilized fresh milk with a composite strain consisting of lactobacillus delbrueckii subsp. Bulgaricus, streptococcus salivarius subsp. Thermophilus, bifidobacterium animalis subsp. Lactis, plant lactobacillus, bifidobacterium breve, lactobacillus paracasei, lactobacillus helveticus, lactobacillus rhamnosus and bifidobacterium longum subsp. Longum, and fermenting; and adding beta-glucan into the fermented yoghourt to obtain the high-stability beta-glucan yoghourt. Before beta-glucan is added, the compound bacterial strain is added into the milk, protein in the milk can be gathered under the action of the compound bacterial strain to form a three-dimensional curd network, so that the flowability of a system is reduced, then glucan is added, and the glucan can be uniformly dispersed in curd gaps, so that the glucan is prevented from being excessively combined with the protein in the milk; the stability of a yoghourt system is improved.

To provide an oral composition for effectively activating plasmacytoid dendritic cells (pDCs).SOLUTION: An oral composition for activating plasmacytoid dendritic cells (pDCs), comprising Lacticaseibacillus rhamnosus CRL1505, wherein the composition is preferably intended for immune activation. The oral composition for activating pDCs is considered to: regulate both innate immunity and acquired immunity; act on an overall immune function, maintain a normal immune function, and maintain good physical conditions. The present invention also provides an oral composition for immune activation characterised in that it comprises Lacticaseibacillus rhamnosus CRL1505, wherein the immune activation is intended for symptoms such as nasal congestion.SELECTED DRAWING: Figure 1

The invention discloses L-rhamnose isomerase and application thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the L-rhamnose isomerase is obtained by performing the following mutation on an amino acid sequence as shown in SEQ ID NO.1: the 258th amino acid is mutated from D to Q. Compared with the prior art, the L-rhamnose isomerase mutant D258Q is obtained by mutating wild type L-rhamnose isomerase, and compared with the wild type L-rhamnose isomerase, the L-rhamnose isomerase mutant D258Q is higher in enzyme activity and longer in half-life period, so that when the L-rhamnose isomerase mutant D258Q is used for catalyzing the conversion of D-psicose into D-allose, the L-rhamnose isomerase mutant D258Q has the advantages that the enzyme activity is higher, and the half-life period is longer; the catalytic capability is stronger and more durable, and the conversion efficiency of the reaction and the yield of D-allose are improved.

The invention provides a probiotic composition for preventing and / or inhibiting oral pathogens as well as a derivative product, a preparation method and application of the probiotic composition, and belongs to the technical field of oral care. The probiotic composition comprises the following bacterial strains in parts by mass: 90 to 0.45 part of a lactobacillus rhamnosus bacterial strain A2114, 10 to 0.3 part of a plant lactobacillus bacterial strain A2124, 80 to 0.4 part of a pediococcus pentosaceus bacterial strain A2135, 250 to 0.25 part of a lactobacillus reuteri bacterial strain A21350, and 40 to 0.2 part of a plant lactobacillus bacterial strain A2109. The probiotic composition or the metabolite thereof can effectively inhibit oral pathogens such as streptococcus mutans, porphyromonas gingivalis, helicobacter pylori, escherichia coli and staphylococcus aureus. Therefore, the probiotic composition or the metabolite thereof shows a good application prospect in the aspects of preventing and relieving oral problems such as decayed teeth, periodontitis and ozostomia.

The invention relates to the field of medicines, foods or health-care products, in particular to big-fruit hawthorn heteropolysaccharide as well as a preparation method and application thereof. The large-fruit hawthorn heteropolysaccharide is prepared from galacturonic acid, glucuronic acid, mannose, xylose, arabinose, glucose, galactose, fucose and rhamnose. The weight-average molecular weight of the big fruit hawthorn heteropolysaccharide is 81.6 kDa to 157.3 kDa. The product has unique structures of complex monosaccharide composition, low molecular weight, appropriate uronic acid content, low esterification degree and the like; compared with CP which is single in structure and high in esterification, the CP is better in oxidation resistance and bile acid binding capacity; compared with hawthorn polysaccharide with low uronic acid content and high molecular weight, the hawthorn polysaccharide has the advantages that the enzyme inhibition activity is obviously enhanced, and the hawthorn polysaccharide has a wide prospect in development of functional food, health care products or medicines for regulating blood sugar / blood fat, resisting oxidation and preventing metabolic syndromes.

The present invention relates to a microbial combination and a fermented milk and the use thereof, in particular to a multi-strain microbial combination, a fermented milk prepared from the microbial combination and the use of the microbial combination in the fermentation of a camel milk. The microbial composition contains at least two of lactic acid bacteria and yeasts derived from traditional fermented milk products in Xinjiang, including Leuconostoc pseudomesenteroides, Lactobacillus rhamnosus, Debaryomyces hansenii and Kluyveromyces marxianus. The microbial composition ensures that industrially fermented camel milk products have the flavor and nutritional functions of naturally fermented sour camel milk, but with higher quality, better safety and significantly prolonged shelf life. The microbial composition has relatively high acidification efficiency, proteolysis capacity and lactose decomposition capability, can improve the unpleasant flavor of camel milk products industrially fermented by using conventional strains, and has wide application prospects in industrial production.

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention belongs to the technical field of probiotic particles, and particularly relates to probiotic particles for improving intestinal functions as well as a preparation method and application of the probiotic particles. The probiotic particles capable of improving the intestinal function comprise a probiotic core, a first embedding layer, a second embedding layer and a third embedding layer, the probiotic inner core is prepared from plant lactobacillus, bifidobacterium animalis, lactobacillus acidophilus, bifidobacterium longum, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus fermentum, lactobacillus helveticus, streptococcus thermophilus, plant lactobacillus, lactobacillus helveticus and lactobacillus rhamnosus. According to the present invention, the twelve probiotics are contained, and the latest three-layer embedding technology is adopted so as to enhance the storage property and the digestive tract tolerance, such that the product can maintain the beneficial bacterium activity for a long time without refrigeration, and the product is suitable for the crowd with the alteration of the intestinal flora.

The invention relates to the technical field of gene engineering, in particular to an L-rhamnose isomerase mutant, a recombinant plasmid, a mutant strain and application. The amino acid sequence of the mutant is as shown in SEQ ID NO.4, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO.3. A specific mutant gene sequence is designed, a recombinant plasmid pET28a (+)-L-Rhi is successfully constructed, the gene sequence is connected between enzyme cutting sites BamH I and Hind III of an escherichia coli expression vector pET-28a (+) to construct a mutant expression vector (the recombinant plasmid pET-28a (+)-L-Rhi), the mutant expression vector is transformed into an escherichia coli BL21 competent cell, a mutant strain is obtained, and the recombinant plasmid pET-28a (+)-L-Rhi is obtained. The obtained mutant strain can overexpress L-rhamnose isomerase, the conversion rate of D-allose is remarkably improved, the thermal stability of the enzyme is remarkably improved through the design of mutation sites, and the half-life period is effectively prolonged.

The invention relates to the technical field of microorganisms, in particular to a probiotic composition for improving sleep and application, and the probiotic composition comprises lactobacillus paracasei BMC-2020, lactobacillus plantarum MCA-3066, lactobacillus rhamnosus, lactobacillus fermentum and lactobacillus casei. The probiotic composition provided by the invention is safe and efficient, has a prospect of developing a new medicine for improving sleep, and has a clinical practical value; the probiotic composition is used for fermenting the traditional Chinese medicine composition, the obtained traditional Chinese medicine fermentation composition contains probiotics and traditional Chinese medicine fermentation liquor, the probiotics and the traditional Chinese medicine fermentation liquor can effectively achieve a synergistic effect, and the sleep improving efficacy of a traditional Chinese medicine fermentation product is promoted; the traditional Chinese medicine fermented composition can reduce the awakening activity amount and the total awakening time, and has the effect of improving sleep.

The invention belongs to the technical field of biological medicines, and particularly discloses a composition with functions of reducing blood sugar and blood fat as well as a preparation method and application of the composition. Chinese herbal compound medicinal materials are subjected to water extraction and high-temperature and high-pressure sterilization, and lactobacillus rhamnosus SHA113 bacterial sludge is resuspended in a water extract to obtain the composition of lactobacillus rhamnosus SHA113 and the Chinese herbal compound; the traditional Chinese medicine compound composition comprises astragalus membranaceus, raw Chinese yam, hawthorn, gynostemma pentaphylla, liquorice and jujube; the preservation number of the lactobacillus rhamnosus SHA113 is CCTCC (China Center For Type Culture Collection) NO: M 2017838; the lactobacillus rhamnosus SHA113 and traditional Chinese medicine compound composition can remarkably reduce the content of triglyceride and cholesterol in serum, control the fasting blood-glucose level, relieve accumulation of triglyceride and cholesterol in the liver and improve the oxidation resistance of the liver, has wide market potential and application prospects, and has wide application prospects. The compound can be applied to preparation of drugs for reducing blood sugar and blood fat.

The invention discloses a seed pelleting formula for improving salt tolerance of suaeda salsa in coastal saline-alkali soil and a processing method, the pelleting formula comprises 348-492 parts of a filler, 348-492 parts of a binder, 348-492 parts of a water-retaining agent and 348-492 parts of a biological stimulant, and the filler comprises attapulgite, talcum powder and vermiculite; the binder is 73-89 parts and comprises sodium carboxymethyl cellulose, polyvinyl alcohol and starch; the water-retaining agent accounts for 30 to 42 parts, and the water-retaining agent is polyacrylamide; the biological stimulant is prepared from the following components in parts by weight: 20-78 parts of yeast metabolite, potassium fulvate, seaweed essence, rhamnolipid and a microbial agent; the processing method comprises the steps of seed selection, raw material preparation, layered coating, low-temperature drying, selection and sieving, and polishing and shaping. According to the invention, a layered coating process is adopted to break through a traditional single mixed coating mode, an isolation breathable microenvironment is firstly constructed by the filling layer, then growth-promoting stress-resistant nutrient substances are injected by the active layer, and finally, the shaping layer is used for locking and shaping and strengthening protection, so that the seeding performance, salt tolerance, germination activity and seedling stress resistance of the pellets are remarkably improved.

A composition includes postbiotics comprising two or more of the following components: Lactobacillus acidophilus, Lactobacillus rhamnosus, and Saccharomyces boulardii; wherein the postbiotics are dead, whole-cell postbiotics. A method of providing to a subject an immunomodulatory, immune regulatory and / or immune boosting effect through administering the composition is also provided. A method of making the postbiotic composition is also provided.

The invention relates to the technical field of gene engineering, in particular to an L-rhamnose isomerase mutant, a recombinant plasmid, a mutant strain and application. The amino acid sequence of the mutant is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. A specific mutant gene sequence is designed, a recombinant plasmid pET28a (+)-L-Rhi is successfully constructed, the gene sequence is connected between enzyme cutting sites BamH I and Hind III of an escherichia coli expression vector pET-28a (+) to construct a mutant expression vector (the recombinant plasmid pET-28a (+)-L-Rhi), the mutant expression vector is transformed into an escherichia coli BL21 competent cell, a mutant strain is obtained, and the recombinant plasmid pET-28a (+)-L-Rhi is obtained. The obtained mutant strain can overexpress L-rhamnose isomerase, the conversion rate of D-allose is remarkably improved, the thermal stability of the enzyme is remarkably improved through the design of mutation sites, and the half-life period is effectively prolonged.

The invention relates to microbial colorant compositions and associated processes to produce the same. Microbial colorant compositions are produced by combining microbially derived pigment molecules and microbial biosurfactants. The pigment molecules are obtained either directly from a fermentation broth or by extracting a precursor and transforming it into a pigment using chemical or enzymatic processes. A separately produced biosurfactant, such as a rhamnolipid or surfactin, is added to the obtained pigment molecule to create a pre-dispersed formulation. The biosurfactant may be added at various steps of This approach improves pigment dispersion, solubility, and substrate compatibility, enabling stable aqueous formulations without synthetic additives. The resulting compositions are suitable for wide range of applications including in textiles, food, cosmetics, and polymer materials. Processes for producing and combining the pigment and biosurfactant are also disclosed, including variations in fermentation, extraction, and formulation stages.

The invention discloses application of uncaria acidic polysaccharide URP-2 in preparation of an anti-esophageal cancer drug, and belongs to the technical field of antitumor of medicinal plant polysaccharide. According to the method, a method for extracting the uncaria total polysaccharide by boiling water and precipitating the uncaria total polysaccharide by ethanol is adopted, and a DEAE DE-52 cellulose column and sephadex column purification technology is combined, so that the separation of the uncaria acidic polysaccharide component is realized, and the uncaria acidic polysaccharide URP-2 is obtained. The uncaria acidic polysaccharide URP-2 comprises the following components in mole percent: 14.11% of arabinose, 12.64% of rhamnose, 6.48% of galactose, 5.00% of glucose and 61.77% of galacturonic acid. Experiments show that the uncaria acidic polysaccharide URP-2 has remarkable anti-esophageal cancer activity, so that a potential experimental basis and a new strategy are provided for applying the uncaria acidic polysaccharide URP-2 to clinical treatment of esophageal cancer.

The invention discloses emblic leafflower fruit polysaccharide with sugar-controlling and lipid-lowering activity as well as a preparation method and application of the emblic leafflower fruit polysaccharide. The polysaccharide is prepared by taking fresh phyllanthus emblica pulp as a raw material through hot water extraction, yeast fermentation, desorption after XAD-16 macroporous resin adsorption, alcohol precipitation, ultrafiltration and DEAE-52 cellulose column purification. The low-molecular-weight gulcomannan is separated from phyllanthus emblica for the first time, and monosaccharide composition of the gulcomannan mainly comprises glucose, mannose and galactose and contains trace rhamnose and xylose. The polysaccharide has sugar-controlling and lipid-lowering active action targets in the whole digestive tract (the upper digestive tract: glycolipid digestion and absorption enzymes alpha-amylase, alpha-glucosidase and pancreatic lipase inhibitory activity, starch hydrolysis delay, bile acid adsorption capacity and cholesterol micelle dissolution inhibition capacity; in the lower digestive tract, the multiplication promoting capacity of glycolipid metabolism-related probiotics) shows extremely high biological activity, and can be applied to food and health care products.

The invention discloses a Pseudomonas putida high-yield rhamnolipid fermentation medium based on a step-by-step optimization strategy, an optimization method and application thereof, through the step-by-step strategy of component screening-single-factor optimization-multi-factor interactive optimization, a mixed carbon source and a mixed nitrogen source are taken as cores, and a Plackett-Burman test, a steepest climbing test and Box-Behnken response surface design are combined, so that the high-yield rhamnolipid fermentation medium for the pseudomonas putida high-yield rhamnolipid is obtained. Optimizing to obtain a special fermentation culture medium; two genetic engineering strains estA-2 and estA-3 are constructed by heterologous expression of key genes, and the supply and extracellular transport efficiency of a rhamnolipid synthesis precursor is enhanced; the recombinant strain is applied to the optimized culture medium, and efficient production of a shake flask and a 5L fermentation tank is achieved. The rhamnolipid yield of the estA-3 strain in a 5L fermentation tank reaches 35.59 + / -2.18 g / L, the conversion rate is 0.282 g / g, the productivity is 0.404 g / L / h, the rhamnolipid yield, the conversion rate and the productivity are obviously superior to those in the prior art, and a key technical support is provided for industrial production of rhamnolipid.

The invention discloses a production method of fucosylated oligosaccharide. The core of the method is as follows: the GDP-D-rhamnose is converted into the GDP-L-fucose by using the GDP-D-rhamnose-3, 5-epimerase; the GDP-D-rhamnose is obtained by converting the GDP-D-mannose-4, 6-dehydratase and the GDP-4-keto-6-deoxy D-mannose reductase by taking the GDP-D-mannose as a substrate, and the GDP-D-rhamnose is obtained by taking the GDP-D-mannose as a substrate. The invention relates to a method for producing a fucosylated oligosaccharide, which is characterized in that a GDP-D-mannose-4, 6-dehydratase, a GDP-4-keto-6-deoxyD-mannose reductase, a GDP-D-rhamnose-3, 5-epimerase and a fucosyltransferase are expressed in a genetically modified host cell, and the fucosylated oligosaccharide can be produced by the way mentioned above.

The invention discloses lactobacillus rhamnosus 1.0320, a metagen as well as a preparation method and application of the lactobacillus rhamnosus 1.0320 and the metagen, and belongs to the technical field of microorganisms. The invention provides lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on April 8, 2018, and the preservation number of the lactobacillus rhamnosus 1.0320 is CGMCC (China General Microbiological Culture Collection Center) NO.15557. The lactobacillus rhamnosus 1.0320 can be used for preparing the lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 and the metagen thereof provided by the invention have the effects of improving the intestinal barrier and relieving the inflammatory bowel disease.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating pneumonia, and belongs to the technical field of biological medicine. The probiotic composition comprises sophora flower bud powder, a broccoli seed aqueous extract, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Research finds that the probiotic composition can significantly relieve pulmonary edema caused by pneumonia and also can significantly reduce the level of inflammatory factors in pneumonia, so that the probiotic composition has the effect of preventing and / or treating pneumonia, and more choices are provided for clinical drugs for preventing and / or treating pneumonia.